Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LENTI-BC
- Development stage
- Preclinical
- Lead developer
- Theravectys
- Modality
- Vaccines & Immunotherapeutics
01
Overview
LENTI-BC is a preclinical-stage, lentiviral vector-based therapeutic vaccine being developed by Theravectys for the treatment of breast cancer. Utilizing Theravectys's proprietary lentiviral vector vaccination platform, the vaccine is designed to deliver tumor-associated antigens directly to dendritic cells in vivo. This targeted delivery aims to overcome immune tolerance and stimulate a robust, long-lasting cellular immune response, specifically activating cytotoxic CD8+ T cells and CD4+ helper T cells to target and eliminate breast cancer cells.
Beyond the preview
Go deeper on LENTI-BC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LENTI-BC.